Liminatus Pharma, Inc. (LIMN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Liminatus Pharma, Inc. on February 17, 2026, with the closing of the transaction occurring on February 18, 2026. The Company, an emerging growth company incorporated in Delaware, announced the pricing and closing of a "best efforts" public offering to raise capital for clinical trials, research and development, sales and marketing, and working capital.
Key Financial Metrics and Transaction Details
The offering consisted of a combined public offering price of $0.29 per unit. The specific components and financial outcomes are as follows:
- Securities Issued: 8,270,000 shares of common stock; 5,543,000 pre-funded warrants; and 13,813,000 common stock purchase warrants (exercisable for up to 20,719,500 shares).
- Net Proceeds: Approximately $3.46 million after deducting estimated offering expenses and placement agent fees.
- Placement Agent Fees: A cash fee of 8.0% of aggregate gross proceeds, reimbursement of out-of-pocket expenses up to $100,000, and issuance of warrants to purchase 690,650 shares (5.0% of common stock sold).
- Warrant Terms: Public warrants have an exercise price of $0.29 and expire in five years. Placement Agent warrants have an exercise price of $0.319 (110% of offering price) and expire in five years.
The filing text does not provide clear values for the Company's current revenue, profit, cash flow, margins, or total debt levels outside of the context of this specific transaction.
Material Changes and Agreements
On February 17, 2026, the Company entered into a Securities Purchase Agreement and a Placement Agency Agreement with Maxim Group LLC. Material covenants include:
- Issuance Restrictions: The Company agreed not to issue or announce the issuance of common stock or convertible securities for 180 days following the closing date, subject to exceptions.
- Variable Rate Transactions: The Company is restricted from entering into Variable Rate Transactions for 180 days post-closing.
- Lock-Up Agreements: Directors and executive officers agreed to a 180-day lock-up period, prohibiting the sale or disposal of common stock or convertible securities without the Placement Agent's consent.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds primarily for clinical trials, research and development, sales and marketing, and general corporate purposes. The filing does not contain specific forward-looking guidance regarding future revenue or profitability, nor does it detail specific risks beyond standard contractual obligations and the dilutive nature of the warrant issuance.
Key Facts for Investor Verification
- Verify the final closing date and exact net proceeds received, as the filing states "approximately $3.46 million."
- Confirm the total number of shares outstanding post-offering to assess dilution from the 8,270,000 new shares and the potential 20,719,500 shares from public warrants.
- Review the specific exceptions to the 180-day lock-up and issuance restrictions in the attached Purchase Agreement (Exhibit 10.2).
- Monitor the Company's cash burn rate relative to the $3.46 million raised to determine runway for clinical trials.